news
Robotic capsule could replace injected biologics
MIT researchers have developed a robotic capsule that tunnels through mucus in the GI tract to deliver large oral protein-based drugs like insulin.
List view / Grid view
Insulin
![Sanofi logo on top of building [Credit: HJBC/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Sanofi-1-300x278.jpg)
![Sanofi logo on top of building [Credit: HJBC/Shutterstock.com].](https://www.europeanpharmaceuticalreview.com/wp-content/uploads/Sanofi-1.jpg)
news
Sanofi launches Impact® brand of medicines for low-income countries
Sanofi Global Health — a nonprofit unit of Sanofi set up in 2021 — has launched Impact®, a new brand of standard of care medicines dedicated for nonprofit distribution in 40 of the world’s lower-income countries.
news
EMA’s human medicines committee (CHMP) Feb meeting highlights
Highlights of the February 2022 meeting of EMA’s human medicines committee (CHMP) include the recommendation of 13 medicines for approval, along with updates to other drugs and COVID-19 vaccines.
podcasts
EPR Podcast Episode 8 – Oral biologic drug delivery with Giovanni Traverso, MIT
How close are we to oral biologic drug delivery? Will biomedical devices be essential in overcoming drug delivery challenges? Discover all this and more in this podcast with MIT's Assistant Professor Giovanni Traverso.
news
Pill may replace injections for monoclonal antibody treatments
An innovative new pill can deliver large quantities of monoclonal antibodies and other drugs into the stomach lining after swallowing.
news
FDA approves first interchangeable biosimilar insulin product
The first interchangeable biosimilar insulin product will help increase access and affordability of insulin for diabetics.
news
Diabetes treatment pump trial begins in Canada
A Phase I trial evaluating Adocia’s BioChaperone® Lispro Pramlintide formulation for insulin pump delivery in type 1 diabetics has begun.
news
New process for producing synthetic insulin developed
Researchers say that their novel way to produce synthetic insulin could also be used to create at least eight other drugs.
news
Novo Nordisk offers free 90-day insulin supply to patients due to COVID-19
Novo Nordisk has set up a programme to allow patients in the US experiencing financial hardship because of COVID-19 to receive free insulin for 90 days.
article
Limiting shortages: steps for the UK to strengthen drug supply
Dr Sam Roscoe explains his recommendations for pharmaceutical companies and supermarkets in the UK to limit reliance on deliveries from overseas, to ease the impact of the COVID-19 coronavirus on drug supply chains.
news
Wearable patch device could provide an affordable insulin therapy for type 2 diabetics
A study comparing the V-Go device administering regular human insulin and rapid acting insulin analogues found they were equally effective and safe at controlling blood glucose.
news
FDA hands Boehringer and Lilly complete response letter for insulin adjunct
Boehringer Ingelheim and Eli Lilly have received a complete response letter from the US FDA for their sNDA of empagliflozin 2.5mg, an insulin adjunct.
news
COVID-19 update: Eli Lilly assures security of insulin supply
Having become aware of insulin shortages in pharmacies, the company has stated that its products are not backordered and should be available for delivery by wholesalers.
news
FDA transitions to new regulatory pathway for biosimilars
The US FDA will now approve biosimilars via a new regulatory pathway to help grow the competition between biologic products.
news
UK bans parallel exporting of crucial medicines to help COVID-19 patients
The UK government has announced that the parallel export of certain essential medicines is banned, to preserve drugs for the treatment of coronavirus patients.
